Re: P-32 Chromic phosphate t

["ROB FORREST" <ROB_FORREST.RSO#u#MAILROOM@rsomacserver.rso.upenn.edu>]

                      RE>P-32 Chromic phosphate therapies          3/30/95
Dale,

I think your answer is in 10 CFR 35.315 "Safety precautions" (a) which reads
"For each patient receiving radiopharmaceutical therapy AND hospitalized for
compliance with 35.75 of this chapter, a licensee shall..."

Because most P-32 and other radiopharmeceutical therapies outside of I-131 are
< 30 mCi and therefore don't require hospitalization, the 200 dpm/100
cm2/decontamination requirements should not apply.    Room prep and decon fall
into a gray area if the patient is hospitalized for other reasons.

I'd be interested to hear what others are doing in these situations.

Rob Forrest
UPENN
(The above statements are my opinion, no one else reviewed them, approved them,
and I doubt anyone would even think about taking credit for them)

I also apologize if half of this message was posted earlier... I was a little
quick on the send button.

--------------------------------------
Date: 3/30/95 3:25 PM
To: ROB FORREST
From: radsafe@romulus.ehs.uiuc.edu
Received: by rsomacserver.rso.upenn.edu with SMTP;30 Mar 1995 15:23:13 +1000
Received: from romulus.ehs.uiuc.edu (romulus.ehs.uiuc.edu [128.174.74.24]) by
vixen.cso.uiuc.edu (8.6.12/8.6.12) with SMTP id OAA18387; Thu, 30 Mar 1995
14:22:58 -0600
Received: by romulus.ehs.uiuc.edu (NX5.67d/NeXT-2.0)
	id AA03030; Thu, 30 Mar 95 14:22:04 -0600
Date: Thu, 30 Mar 95 14:22:04 -0600
Message-Id:  <9503301411.aa27105@radpro.radpro.uchicago.edu>
Errors-To: melissa@romulus.ehs.uiuc.edu
Reply-To: radsafe@romulus.ehs.uiuc.edu
Originator: radsafe@romulus.ehs.uiuc.edu
Sender: radsafe@romulus.ehs.uiuc.edu
Precedence: bulk
From: "Dale E. Boyce" <dale@radpro.uchicago.edu>
To: Multiple recipients of list <radsafe@romulus.ehs.uiuc.edu>
Subject: P-32 Chromic phosphate therapies
X-Listserver-Version: 6.0 -- UNIX ListServer by Anastasios Kotsikonas
X-Comment:  Radiation Safety Distribution List 

The use of P-32 chromic phosphate for intraperitoneal
treatment of ovarian cancer has increased here.  In the
past, one or two patients a year were treated.  Our
hospital is trying to determine if post surgical treatment
will assist in getting a cure.  In the past it was used
for paliative treatment of metastatic disease.

We had always operated under the assumption that the
insoluble colloid was not excreted.  Yesterday, out of
curiousity, one of our medical physicist acquired a urine
sample from a patient, which we found to contain about
10 nCi/ml of P-32.

Question, has anyone out there been prepping and decontaminating
P-32 rooms?  Have you had any contamination problems?
We are going to check the next few patients more carefully,
but wonder what the body of knowledge has to say wrt. P-32.

Dale E. Boyce
dale@radpro.uchicago.edu